CLCN2
ENSG00000114859
Target class
Ion channel
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- ClinGen gene-disease validity
- Refuted
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- CLCN2
- Gene name
- Chloride voltage-gated channel 2
- Gene symbol
- CLCN2
- Protein name
- Chloride channel protein 2 (ClC-2)
- CLC2
- EJM6
- ClC-2
- Gene biotype
- Protein coding
- Gene family
- CLC chloride channel and transporter family
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 26.78
- Tissue specificity (Gini)
- 0.424
- Tissue specificity (tau)
- 0.819
- KEGG gene identifiers
- hsa:1181
- Reactome pathways
- R-HSA-2672351
- Protein interaction confidence
- 0.820444
- Protein interaction partners
- 9
- End position
- 184363274
- Start position
- 184346185
- Chromosome
- 3
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Basolateral cell membrane
- Multi-pass membrane protein . Cell projection, dendritic spine membrane
- Multi-pass membrane protein . Cell projection, axon . Note=Sorting to the basolateral membrane is mediated by AP-1 clathrin adapter (PubMed:16155254). Localizes at axon initial segments and dendritic shaft and spikes. Colocalizes with HEPACAM and GFAP at astrocyte end-foot in contact with brain capillaries and other glial cells (By similarity) (PubMed:22405205, PubMed:23707145). .
- Cytosol
- PubMed 22405205
- PubMed 23707145
- PubMed 29403011
- PubMed 36964785
- PubMed 38345841
- PubMed 16155254
- Tissue specificity (tau)
- 0.81912
- Expression inequality (Gini)
- 0.424277
Expression in transcripts per million
- Nerve - Tibial
- 26.78
- Testis
- 25.51
- Brain - Cerebellum
- 16.25
- Brain - Cerebellar Hemisphere
- 14.21
- Ovary
- 11.56
Expression in transcripts per million
- Nerve - Tibial26.78
- Testis25.51
- Brain - Cerebellum16.25
- Brain - Cerebellar Hemisphere14.21
- Ovary11.56
- Uterus10.4
- Cervix - Endocervix8.39
- Colon - Transverse8.38
- Small Intestine - Terminal Ileum7.35
- Pituitary7.01
- Cervix - Ectocervix6.84
- Brain - Spinal cord (cervical c-1)6.78
- Fallopian Tube6.56
- Adrenal Gland6.36
- Thyroid6.36
- Artery - Aorta5
- Prostate4.71
- Kidney - Medulla4.48
- Vagina4.44
- Bladder4.26
- Colon - Sigmoid4.25
- Brain - Cortex4.11
- Artery - Coronary4.05
- Artery - Tibial3.86
- Esophagus - Gastroesophageal Junction3.67
And 29 more, listed on the interactive page.
- GO:0006911
- GO:0032347
- GO:0005886
- GO:0016323
- GO:0043209
- GO:0097450
- GO:0005247
- GO:0017081
Related records
Trials (428)
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole
- A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
- A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
- A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
- A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
- A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
- A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
- A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults
Drugs (4)
- Cobiprostone Chloride channel protein 2 activator
- Fenamic acid
- Lubiprostone Chloride channel protein 2 opener
- Omeprazole